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ABSTRACT
Personal health devices can enable continuous monitoring of health
parameters. However, the benefit of these devices is often directly
related to the frequency of use. Therefore, adherence to personal
health devices is critical. This paper takes a data mining approach
to study continuous glucose monitor use in diabetes management.
We evaluate two independent datasets from a total of 44 subjects
for 60 - 270 days. Our results show that: 1) missed target goals
(i.e. suboptimal outcomes) is a factor that is associated with wear-
ing behavior of personal health devices, and 2) longer duration of
non-adherence, identified through missing data or data gaps, is
significantly associated with poorer outcomes. More specifically,
we found that up to 33% of data gaps occurred when users were in
abnormal blood glucose categories. The longest data gaps occurred
in the most severe (i.e. very low / very high) glucose categories.
Additionally, subjects with poorly-controlled diabetes had longer
average data gap duration than subjects with well-controlled di-
abetes. This work contributes to the literature on the design of
context-aware systems that can leverage data-driven approaches
to understand factors that influence non-wearing behavior. The
results can also support targeted interventions to improve health
outcomes.
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•Human-centered computing→ User studies; Empirical stud-
ies in HCI .
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1 INTRODUCTION
Personal health devices (PHD), often in the form of mobile and
wearable systems, are particularly useful for pervasive monitoring
of health status and vital signs [2, 5]. These technologies provide
unique opportunities for early diagnosis of diseases, management of
chronic conditions, and prompt-response to emergency situations
[3]. PHDs have been employed for monitoring of many conditions
such as heart disease [27], Parkinson’s disease [34], and diabetes
[10]. Despite, the potential advantages of these technologies, the
benefit is often proportional to the frequency of use [22, 36]. For
example, the American Diabetes Association (ADA) states that
frequency of PHD use, specifically continuous glucose monitors, is
the "greatest predictor" for lowering hemoglobin A1C - a primary
clinical outcome for diabetes management [1]. Therefore, the notion
of adherence to PHDs is critical. A person who uses these devices as
intended often achieves better outcomes. Conversely, a person who
does not use these devices as intended often achieves suboptimal
outcomes. However, it is important to note that wearable PHDs are
facilitators, and not drivers, of health behavior change [29].
There are several definitions of adherence [40]. However, in
this paper, we adopt the definition that adherence means comply-
ing to a recommended regimen to achieve the best outcome. A
recommended regimen can be in the form of guidelines such as
taking 10,000 steps per day or prescriptive such as monitoring
blood glucose before and after meals. Given the rise of commercial
wearable devices in today’s society, recent work has focused on
adherence to non-prescription PHDs such as physical activity track-
ers [11, 16, 40]. However, adherence to prescription PHDs such as
inhalers for asthma control [22] or continuous glucose monitors
used in diabetes management [15] is arguably more important. In
the case of asthma or diabetes, there can be an immediate risk or
an undesired health event associated with non-adherence.
This paper focuses on a case study of adherence to PHDs in
diabetes care for two key reasons. Firstly, diabetes is the 7th leading
cause of death and it affects up to 9.4% of people in the U.S. [14]. This
is a significant fraction of the population. Secondly, and equally as
important, PHDs in diabetes management are relatively advanced as
there exists wearable devices for continuous monitoring of the most
relevant biomarker (i.e. blood glucose) [10, 36]. Similar devices for
management of other chronic conditions (e.g. heart disease, mental
illness, and obesity) are lagging. However, extensive effort is being
committed to develop wearable alternatives for continuous 24-hour
monitoring of relevant biological and behavioral markers [5, 28, 31].
We envision that findings from this study on diabetes can inform
PHD data analysis in other domains.
A revolutionary innovation in diabetes care was the develop-
ment of a continuous glucose monitor (CGM). As shown in Figure
1, it is a minimally-invasive wearable device that enables real-time
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Figure 1: Personal health devices for diabetes care: A con-
tinuous glucose monitor (left), blood glucose display and in-
sulin pump (right) [8].
monitoring of blood glucose (BG) levels from sampling concentra-
tions in the interstitial fluid [10]. In comparison to intermittent
self-monitoring using glucose meters, CGMs enable the ability to
dynamically adapt management strategies such as food intake, ex-
ercise, and medication-use to real-time glucose trends. Proper use
of CGMs has been shown to reduce risk factors of diabetes such as
severe low blood glucose and micro-/macro-vascular complications
[9, 10, 35–37]. However, as is the case with any wearable PHDs,
people do not always use them as recommended [15, 35, 37].
The objective of this paper is to assess factors that affect ad-
herence (i.e. wearing or use behavior) of personal health devices.
More specifically, we seek to investigate: "whether and to what
extent achieving target glycemic goals affect wearing behavior of
continuous glucose monitors used in diabetes management." Based
on data from larger project, we evaluated 60 - 270 days of CGM
data from 44 subjects with diabetes and found that:
(1) Performance toward target goal and age are two factors that
influence adherence to PHD.
(2) Longer duration of data gaps occurred in suboptimal BG
categories and the longest data gaps occurred in the most
severe (i.e. very low/very high) BG categories.
(3) Subjects with poorly-controlled diabetes had on average
longer data gap durations, indicative of worse adherence,
than subjects with well-controlled diabetes.
(4) Older subjects (age: > 40-yrs) had significantly worse adher-
ence to PHDs, evident by longer data gap durations, com-
pared to younger subjects (age: 24 - 40-yrs).
(5) PHD adherence varied across individuals and showed to be
subject-dependent.
A key recommendation from this work is for development of
context-aware PHDs that implement data-driven adherence anal-
ysis in embedded algorithms to improve wearing behavior, guide
interventions, and positively affect health outcomes. In the case
of CGM use in diabetes management, non-wearing behavior influ-
enced by suboptimal BG can be identified based on the BG category
users were in prior to the start of data gaps (or missing data events).
Adherence analysis to PHDs is important in many health applica-
tions [17]. Therefore, we expect results from this work to inform
research in other domains. However, a potential limitation of this
work is the assumption that data gaps or missing data is directly
indicative of non-adherence to PHDs, specifically CGMs in this
study.
2 RELATEDWORK
This section reviews relevant literature on personal health data and
interpretation with a focus on non-prescription and prescription
PHDs.
2.1 Adherence to Non-prescription PHDs
Adherence to PHDs has more commonly been studied for con-
sumer wearable systems such as physical activity trackers and
smartwatches [11, 12, 16, 20, 24, 40, 43]. Jeong et al. evaluated
smartwatch use amongst 50 college students to understand factors
that affect wearing behavior [16]. They found that participants
wore their smartwatches for an average of 10.9 and 8.4 hours/day
on weekdays and weekends, respectively. Users of such wearable
devices were classified into three categories, namely, work-hour
wearers, day-time wearers, and all-day wearers. However, only a
small percentage of users (about 10%) are all-day wearers, most
users tend to take off their device before bed-time [16, 21]. Tang
and Kay [39] studied adherence to long-term FitBit users. They
showed that users benefited from a calendar-view display of daily
and hourly adherence in association with the adherence goal. As ex-
pected, users cannot achieve the optimal benefit from PHDswithout
wearing the device. A large scale population study by Doherty et
al. [11] found that age and time of day are key variables associated
with compliance to physical activity trackers. Additionally, several
studies have shown that there is high abandonment of consumer
wearable devices after about 2-months [7, 19, 38]. Some reasons for
abandonment include devices not fitting with user’s conceptions of
themselves, discomfort with information revealed, and the collected
data not being perceived as helpful for continued use [12, 19]. These
findings are applicable for leisurely-used, non-prescription PHDs,
however, they do not exactly translate to prescription PHDs needed
for management of a health condition.
2.2 Adherence to Prescription PHDs
In a review on adherence to inhaler devices, non-adherence was
found to be influenced by patient knowledge/education, conve-
nience of the device, age, adverse effects, and associated costs [22].
Likewise some factors that have been identified which limit ad-
herence to CGM devices used in diabetes management include
cost, sensor discomfort, device inaccuracy, and general usability
issues [10, 30, 36, 37]. A 6-month clinical trial found that the mean
CGM adherence in patients with type 1 diabetes differed across
age groups with the highest adherence found in adults (ages: > 18
years) and lowest adherence found in adolescents (ages: 12 - 18
years). [15]. Other studies have found that psychosocial factors
such as coping skills, body image, and support from loved ones are
associated with the use of CGMs [35, 37]. The aforementioned stud-
ies highlight demographic, usability, cost, and psychosocial factors
that influence accumulative adherence, however, little effort has
focused on understanding contextual factors that affect day-to-day
adherence. The recent papers by Raj et al. [32, 33] highlight the
importance of evaluating clinical data from PHDs in context. More
specifically, they show that management of chronic conditions
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such as diabetes varies in different contextual settings influenced
by time, location, people, and emotional state. Unlike the aforemen-
tioned work, this paper takes a quantitative, data-driven approach
to investigate whether and to what extent management outcomes
influence adherence to PHDs. This insight can inform the design of
context-aware algorithms that include adherence analysis to iden-
tify subject-specific factors associated with non-wearing behavior,
provide target interventions, and improve outcomes.
3 BACKGROUND
Diabetes is characterized by impaired glucose metabolism. There-
fore, a person with diabetes should be constantly aware of the many
factors that can affect their body’s glucose levels including food,
activity, medication, environment, and behaviors in daily living
[4]. The primary management goal is to minimize the occurrence
of hypoglycemic (i.e. low BG) and hyperglycemic (i.e. high BG)
events [10, 30, 36]. Based on clinical research [9], there are five BG
categories that are important, namely:
(1) Very Low: Periods of BG readings < 54 mg/dL. This is con-
sidered a clinically-significant hypoglycemic event that may
require immediate action.
(2) Low: Periods of BG readings between 54 - 70 mg/dL. It is
recommended to set a CGM hypoglycemia alert for this
category to reduce the risk of a more severe event.
(3) Normal: Periods of BG readings between 70 - 180 mg/dL.
This is considered the target range and the goal is to maxi-
mize time spent in this range.
(4) High: Periods of BG readings between 180 - 250 mg/dL. It
is recommended to set a CGM hyperglycemia alert for this
category to reduce the risk of a more severe event.
(5) Very High: Periods of BG readings > 250 mg/dL. This is
considered a clinically-significant hyperglycemic event that
may require immediate action.
In this work, we use the above categorization of BG readings
to evaluate adherence and wearing behavior of CGMs amongst
persons with diabetes. It is important to note that CGMs are not
perfect and can have inaccuracies in the range of +/- 10% [10, 36].
Additionally, majority of these devices need to be calibrated us-
ing conventional finger-prick method and a blood glucose meter
[9]. Nonetheless, CGMs are the gold standard PHD for real-time
monitoring of BG in diabetes [42], therefore, they were used in this
study.
4 DATA DESCRIPTION AND
PRE-PROCESSING
All the data used in this study was contributed to the research
project by members of online diabetes communities [26, 41], primar-
ily patients with Type 1 Diabetes. Table 1 provides an overview of
two unique CGM datasets analyzed in this work. Dataset-1 includes
60 days of recordings from 10 subjects with diabetes while dataset-2
includes 100 - 270 days of recordings from 34 subjects with diabetes.
There was no overlap between subjects across both datasets. As
shown in Table 1, there was a fair split of well-controlled (52%) vs.
poorly-controlled (48%) subjects with diabetes based on the ADA’s
recommendation to maintain hemoglobin A1C < 7% (equivalent to
an average BG < 154 mg/dL) [1, 25]. Figure 2 presents stacked bar
plots showing subject-level BG distributions across the five notable
categories. In dataset-1, subjects 1, 4, 8, 9, and 10 are examples of
persons with well-controlled diabetes (i.e. average BG < 154 mg/dL
or estimated A1C < 7%). Meanwhile, in dataset-2, subjects 5, 11, 16,
and 24 are examples of persons with poorly-controlled diabetes (i.e.
average BG > 154mg/dL or estimated A1C > 7%).
As part of the data-cleaning step, we removed duplicate, incom-
plete, and invalid samples. A valid data sample is one that includes a
date, timestamp, and glucose reading in the range of 40 - 400 mg/dL.
The data-cleaning step reduced dataset-1 and dataset-2 by 4.28%
and 18.89%, yielding 152,477 and 1,513,398 samples, respectively.
Based on today’s technology, CGMs record a glucose value approx-
imately every 5 minutes with the highest sampling rate being one
sample every 1 minute upon the user’s request [10, 13]. Figure 3
shows a probability density function of the sampling period and
confirms that approximately 99% of our dataset was recorded every
5 minutes with a less than 1% sampled every 1 - 4 minutes. Given
that a CGM is a wearable PHD, the user decides if and when to
wear it. Therefore, missing data is not uncommon. The rest of our
analysis investigates CGM adherence and influential factors that
are explainable from the dataset.
5 ANALYSIS
Our focus is to understandwhether and to what extent management
outcomes (i.e. achieving target goals) affect wearing behavior of
CGMs. Toward this goal, we:
(1) Investigate CGM wear time and explore sample distribution
across the five key BG categories discussed in the "Back-
ground" section.
(2) Characterize periods of missing data (known as data gaps
in this work) by duration and distribution in the relevant BG
categories.
(3) Perform statistical tests (i.e. One-way ANOVA and Two-
Sample T-tests) to evaluate the significance of data gap du-
rations in different BG categories.
(4) Investigate the duration of data gaps in normal vs. abnormal
BG categories on subject- and group-levels, using subgroups
based on management- and age-criteria.
5.1 CGMWear Time
As defined in prior work [24, 40], wear time is a count of the number
of hours in a day that a PHD was worn. In this study, missing data
was used as a proxy for calculating wear time of CGMs given that
there will exist a recorded BG sample whenever the device is worn
and turned-on for use. Figure 4a presents an overview of wear time
as determined by the presence of missing data in both datasets.
We observe that majority of the time users wore their CGM device
for greater than 20 hrs/day. The average wear time was 21.59 (±
2.69) hrs/day and 22.16 (± 3.63) hrs/day for dataset-1 and dataset-2,
respectively. This is indicative of a generally higher adherence to
prescription PHDs compared to non-prescription PHDs such as
physical activity trackers with an average wear time of 10-hrs/day
[16, 21, 24]. However, as shown in Figure 4a there are several cases
in which a CGM user’s wear time in a given day is low (e.g. less
than 15 hrs/day which is below the 25-th percentile mark in both
datasets). We tailored our analysis on understanding such cases and
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Table 1: CGM dataset description. The values in parenthesis represent a breakdown of the number between well-controlled
and poorly-controlled subjects with diabetes based on the ADA glycemic target criteria [1].
Dataset Subjects Ages Days/Subject Total Samples
1 10 (6,4) unknown 60 152,477
2 34 (17,17) 24 - 52 yrs. 100 - 270 1,513,398
(a) Dataset-1 (b) Dataset-2
Figure 2: Stacked bar plots showing subject-level sample distribution across the 5 key BG categories.
Figure 3: Probability Density Function (PDF) and Cumu-
lative Distribution Function (CDF) of sampling periods of
blood glucose readings in dataset-1 and dataset-2.
potential associations with the user’s BG readings (i.e. management
outcomes) prior to the start of a data gap. Contiguous streams of
missing data is used as a proxy for non-adherence to CGMs.
5.2 Sample Distribution in BG Categories
Figure 4b presents an aggregate of CGM sample distribution across
the five key BG categories for all subjects in this study. The highest
percentages of BG readings, 74.4% in dataset-1 and 67.7% in dataset-
2, are in the normal (or target) range. This is representative of
positive management outcomes (i.e. subjects are meeting their goals
in diabetes care). However, ≈ 27% of the data samples are in the high
BG range, with 15.9% in dataset-1 and 19.3% in dataset-2 in the high
range (> 180 mg/dL), and 5.8% in dataset-1 and 7.4% in dataset-2 in
the very high (> 250 mg/dL). Conversely, ≈ 5% of the data samples
are in the low BG range, with about 2.6% in dataset-1 and 4.2% in
dataset-2 in the low range (< 70 mg/dL), and 1.3% of both datasets
in the very low (< 54 mg/dL). As described, low and high BG are
representative of suboptimal management outcomes (i.e. subjects
are not meeting their goal in diabetes care). Given that low BG is
more dangerous in the near-term than high BG value [9], the data
distribution in these categories shows that clinically-significant
categories (very low and very high) occur less often.
5.3 Data Gaps
Figure 5 shows a representative week of CGM data from one subject
and highlights key concepts used in the remainder of this paper
including data gaps and associations with an increase or decrease
in BG. These concepts are further explained below:
• A data gap (δ ) is a period in which there is no BG reading
recorded on the continuous glucose monitor. This represents
periods of contiguous missing data. In the ideal scenario,
users should wear their prescription PHDs throughout the
day (including at night-time) and the device will record BG
data continuously at a preset sampling rate of 5-minutes.
However, the sensor can malfunction or users may take the
device off for different reasons, which can lead to missing
data, i.e., a gap in the continuous recording. Informed by
prior work on missing data and interpolation of CGM sam-
ples [13], a data gap is defined as:
DataGap = δ ≥ 2 ×mode(T ) ∧ δ < 24 × 60 (1)
where δ is the duration in minutes between adjacent data
samples, T is the set of sampling periods in a day, andmode(.)
is the function used to find a number that occurs most often
in a set of numbers. Therefore, a data gap is identified when
there is missing data greater than twice the sampling period
of 5-minutes (i.e. > 10-minutes) and within 24 hours.
• An increase in BG describes the scenario where a user’s last
BG reading before a data gap is lower than the BG reading
after the gap. Based on the BG reading right before a string of
missing data, we categorize data gap events into the five key
categories discussed in the Background section. An increase
in BG readings is most commonly influenced by food intake
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(a) CGM wear time (b) BG sample distribution
Figure 4: Overview of CGM wear time and sample distribution across the 5 key BG categories in both datasets.
and may occur when a user is trending to or in a low BG
category [9, 10]. In our analysis, we investigate whether
there is an association between the presence of data gaps
immediately following low or very low BG readings. We
also evaluate the length of data gaps in each BG category.
This analysis aims to understand the influence of low BG
categories (i.e. suboptimal management) on non-adherence
to CGM use in diabetes care. We seek to answer the question:
are users more likely to take off their CGM during periods of
low BG and return to wearing their device when BG readings
have increased (potentially back to the normal range)?
• A decrease in BG describes the scenario where a user’s
last BG reading before a data gap is higher than the BG
reading after the gap. Based on the BG reading right before
a string of missing data, we categorize data gap events into
the five key categories discussed in the Background section.
A decrease in BG readings is most commonly influenced by
insulin use and may occur when a user is trending to or in
a high BG category [9, 10]. In our analysis, we investigate
whether there is an association between the presence of data
gaps immediately following high or very high BG readings.
Likewise, we evaluate the length of data gaps in each BG
category. This analysis aims to understand the influence of
high BG categories (also suboptimal) on non-adherence to
CGM use in diabetes care. We seek to answer the question:
are users more likely to take off their CGM during periods
of high BG and return to wearing the device when the BG
readings have decreased (potentially back to the normal
range)?
6 RESULTS
In this section, we evaluate wearing behavior of CGM devices in
daily living, with a focus on: 1) non-adherence to CGMs, identified
through data gaps (or missing data events), and 2) factors associ-
ated with non-adherence. It is important to note that unlike non-
prescription PHDs such as FitBits, CGMs are prescription PHDs
that should be worn throughout the day (including at night-time)
to achieve optimal diabetes management.
6.1 Distribution of Data Gaps in BG Categories
For every data gap present, we evaluated the distribution of the
last recorded sample in each of the five key BG categories. Figure 6
(top plot) shows that ≈ 33% of data gaps occurred when users were
in abnormal BG categories (i.e. not achieving management goals).
Furthermore, we investigated subcategories of increase (i.e. positive
difference) and decrease (i.e. negative difference) in BG readings
before and after the data gaps. This analysis aims to understand
the distribution of data gaps for which the last recorded sample
is very high or high and after the gap the first recorded sample
is lower (i.e. a decrease in BG) - see segment B in Figure 5 for
example. This could represent a scenario in which the user has an
extreme reading, takes off their PHD, remedies the situation by
taking medication, then returns to wearing the device after a while.
We observe that data gaps associated with a decrease in BG reading
have higher percentage of cases that start with high and very high
(around 32% in dataset-2 and 34% in dataset-1 – Figure 6 bottom
right) compared to data gaps associated with an increase in BG
reading (around 23% in dataset-2 and 25% in dataset-1 – Figure 6
bottom left). Similarly, for data gaps associated with an increase in
BG reading, it is important to investigate the cases where the last
recorded sample was a low or very low BG reading. We observe that
data gaps with an increase in BG readings have higher percentages
that start with low and very low (around 8% in dataset-2 and 5% in
dataset-1 – Figure 6 bottom left) compared to data gaps associated
with a decrease in BG value (around 4% in dataset-2 and 2% in
dataset-1 – Figure 6 bottom right).
The above analysis shows that there was a higher percentage of
data gaps in the low / very low categories for which the BG value
increased immediately following the data gap. Similarly, there was
a higher percentage of data gaps in the high / very high categories
for which the BG value decreased immediately following the data
gap. This is suggestive of scenarios in which users took off their
prescription PHD when not achieving their goals and returned to
wearing the PHD when their BG started trending toward the target
goal.
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Figure 5: Example of CGM data from one subject in a single week - presented in the same format as a "daily overlay plot".
The horizontal dashed lines indicate threshold values for low and high BG, respectively. Annotated segments show data gaps,
where A, B, and D are data gaps associated with a decrease in BG, while C is a data gap associated with an increase in BG.
Figure 6: Data gap distribution in five key blood glucose categories (top) based on the last recorded sample and subcategories
of BG increase (bottom left) and decrease (bottom right) immediately after the data gap. The parentheses in the legend show
the total number of data gaps present in each dataset.
6.2 Duration of Data Gaps in BG Categories
Figure 7 presents an analysis of the duration of data gaps across
each of the five key BG categories. On average, the length of missing
data events ranges from 15 – 70 minutes (mean = 34.21 minutes in
dataset-1 and 48.79 minutes in dataset-2). A key observation is that
the longest data gaps occurred in the most severe BG categories;
equivalent to when users were farthest away from their target
goal. More specifically, the very low BG category has the longest
data gap associated with an increase in BG after the gap – Figure
7a. For this case, the duration of missing data in the very low BG
category is 1.5 times greater than the duration when users are in
the normal category. Conversely, the very high BG category has
the longest data gap associated with a decrease in BG value after
the gap – Figure 7b. Similarly, the duration of missing data when
users were in the very high categories is up to 1.5 times the duration
when users were in the normal category. This result is suggestive
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of scenarios in which CGM users take off their prescription PHD
when they are in suboptimal BG categories (i.e. not achieving their
management goals). Additionally, users tend not to wear the device
for longer periods when the take-off started in a more severe or
extreme BG category. It is also important to note that there is a
similar trend between data gap duration and BG category across
both independent datasets. This supports that the results observed
are grounded and not biased to one specific dataset.
6.2.1 Statistical Significance of Data Gap Durations. For signifi-
cance testing, we use dataset-2 because it is larger and has more
samples needed for a One-way ANOVA and Two-Sample T-test per
the APA guidelines [18]. We first perform a One-way ANOVA test
for the null hypothesis: “the average duration of data gaps in dif-
ferent BG categories is the same.” Table 2 shows the results which
support to reject the null hypothesis with p-value < 0.01. There-
fore, the average duration of data gaps starting in different BG
categories is not the same. Note that in this table, “SS”, “df”, “MS”,
and “F” represent “Sum of Squares”, “degree of freedom”, “Mean
Square”, and “F-statistic”, respectively. p−values are presents using
three levels of α , i.e., p < .001 (marked as “***”), p < .01 (marked as
“**”), p < .05 (marked as “*”), and p > .05 (marked as “.”).
Next, to compare the average duration of data gaps in different
BG categories, we perform a Two-Sample T-test with H0 : µi = µ j ,
where µi and µ j represents the average data gap duration in two
separate BG categories. For our comparison, we use the average
gap duration of normal BG category as a reference and compare
data gap durations in extreme BG categories, i.e., very low and very
high. We also compare BG categories low vs. very low and high vs.
very high to test for potential differences.
Table 3 shows the Two-Sample T-test results. We observe that the
average gap duration in extreme BG categories is significantly differ-
ent from the duration in the normal BG category. More specifically,
p − value = .0066 for very low vs. normal, and p − value = .0180
for very high vs normal, respectively. Furthermore, we observe that
the average gap duration starting in the very low BG category is
significantly different from the average gap duration starting in
the low BG category (p − value = .0045). Therefore, a very low
BG category has a greater negative impact on users’ adherence to
the device compared to low BG category. On the other hand, the
comparison of average gap durations in very high and high BG
categories do not show a significant difference. This means high
and very high BG categories could have a similar (not different)
negative impact on users’ adherence to the device.
The above finding supports that duration of non-adherence to
CGMs is significantly associated with severity of suboptimal man-
agement. Current CGMs have the ability to alarm users’ when BG
readings are trending toward out-of-target range (or abnormal) val-
ues. However, the utility of this feature is unknown and increased
utility should be encouraged to improve adherence.
6.3 Subject-Level Data Gap Analysis
To further compare the average duration of data gaps during normal
and abnormal (i.e. very low, low, high, and very high) BG categories,
we calculate the difference in these values expressed as a percentage:
%chanдe = T¯abnormal − T¯normal
T¯abnormal
× 100 (2)
Where T¯normal and T¯abnormal is average gap duration computed
in the normal and abnormal BG categories, respectively. Using this
equation, the %chanдe can have one of the following values:
%chanдe =

> 0 if T¯abnormal > T¯normal (3a)
< 0 if T¯abnormal < T¯normal (3b)
0 otherwise (3c)
Figure 8 shows the subject-level analysis of data gaps that started
in the normal vs. abnormal BG categories - using dataset-1 as an
example. Our analysis revealed that 70% of subjects in dataset-1
and 50% of subjects in dataset-2 had longer average gap durations
that started in abnormal BG categories vs. normal BG category (i.e.
case 3a). This further supports the earlier finding that there exists
an association between non-adherence to CGM use and subopti-
mal management (i.e. missing the target goal). It is important to
note that this finding was more prevalent for some subjects (e.g.
subjects 3 and 5) and not applicable to others (e.g. subjects 2 and
9). Therefore, it shows that this phenomenon is subject-dependent
and not generalizable across all people. This aligns with findings
from prior work [11, 16, 24] that factors which influence usage and
adherence patterns to PHDs vary across individuals. The results of
this paper add to this body of work by identifying missed health
goals as a potential factor that contributes to non-adherence.
6.4 Group-Level Data Gap Analysis
Per Table 1, subjects in this study can be broken into subgroups to
support the investigation of potential associations between distinct
groups and non-adherence to PHDs. We performed a Two-Sample
T-test with the null hypothesis: "the average duration of data gaps
in different management- and age-subgroups is the same". This can
be expressed mathematically as H0 : µ1 = µ2, where µ1 and µ2
Table 2: One-way ANOVA table for testing the null hypoth-
esis that "the average duration of data gaps in different BG
categories is the same" - using dataset-2. The result shows to
reject the null hypothesis.
Source SS df MS F Prob>F
Groups 1.12e+05 4 2.81e+04 3.59 0.0062
Error 9.93e+07 12708 7.81e+03
Total 9.94e+07 12712
Table 3: Two-Sample T-test comparing the average data gap
duration in different BG categories - using dataset-2. The
last sample prior to a data gap was used to qualify BG cate-
gories. The results show statistically significant differences
of data gaps in severe BG categories (very low/very high) vs.
the normal BG category.
Comparison df t-statistic significance
Very Low vs. Low 759 2.85 **
Very Low vs. Normal 8629 2.72 **
Very High vs. Normal 9458 -2.37 *
Very High vs. High 3526 -0.94 .
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(a) Data gaps associated with an increase in BG (b) Data gaps associated with an decrease in BG
Figure 7: Average gap durations with error bars across different blood glucose categories for cases when BG reading (a) increase
and (b) decrease after gaps.
(a) Average gap duration with error bars
(b) Percentage (%) change in average gap durations
Figure 8: Subject-level comparison of average gap duration in normal vs. abnormal BG categories for dataset-1.
is the average gap duration for each group. We used the ADA’s
glycemic target criteria of A1C less than 7% (≈ average BG < 154
mg/dL) [1, 25] as a threshold to divide subjects from both datasets
into 2 subgroups: well-controlled (n = 23) vs. poorly controlled (n =
21) subjects with diabetes. Secondly, we used age as another criteria
and the median age of 40.38 yrs as a threshold to divide subjects
from dataset-2 into two equal-size groups (n=17): older vs. younger
subjects.
Table 4 shows the results from this analysis and supports to
reject the null hypothesis that the average gap duration is the same
across groups. We found that there was a statistically significant
difference in the average gap duration (p −value = .00063332) of
subjects with well-controlled diabetes vs. poorly-controlled dia-
betes. A key result is found is that subjects with poorly-controlled
diabetes had a worse adherence to CGMs as evident through the
missing data compared to subjects with well-controlled diabetes.
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Table 4: Two-Sample T-test results for group-level data gap analysis. The result shows statistically significant differences in the
average data gap duration of subgroups. Poorly-controlled subjects (A1C) > 7% and older subjects (age > 40.38 yrs) had longer
data gap durations (i.e. worse adherence to CGMs).
Measure Grouping Avg. gap duration
(threshold) criteria µ1 (err ) µ2 (err ) df t-statistic significance
Glycemic Target <=, 40.01 51.56 17148 -3.42 ***
- A1C (7%) > (1.69) (2.89)
Age >=, 41.91 37.42 13223 2.93 **
(40.38 yrs.) < (1.16) (0.99)
This group-level analysis aligns with the earlier results that subop-
timal outcomes (or missed target goals) is a potential factor that
influences non-adherence to PHDs. Additionally, we found that
older subjects had significantly (p − value = .0034) worse adher-
ence to CGMs, as evident through more missing data, than younger
subjects. This aligns with prior research [11, 22] which identifies
age to be a factor associated with varying adherence levels to PHDs,
and even CGMs more specifically [15]. These findings can guide
tailored PHD design and interventions, although, it is important
to note that there is individual heterogeneity as shown in Fig. 8,
and the group-level finding is not a blanket statement for all people
identified subgroups.
7 DISCUSSION
In this study, we have investigated adherence to PHDs, with a focus
on wearing behavior of CGMs used for diabetes management. We
analyzed two independent datasets from a total of 44 subjects for
60 - 270 days and found that missing data (i.e. data gaps) is not
uncommon. Our results show that suboptimal (i.e. low / high) BG
values is one factor that is associated with non-wearing behavior,
identified through data gaps. Additionally, the length of data gaps
is influenced by management outcomes, such that longer gap dura-
tions (i.e. periods of missing data) are significantly associated with
extreme (i.e. very low / very high) BG categories. It is important
to note that the analysis in this work shows an association, not
causality. Prior work supports that there are many reasons for data
gaps in CGM readings, such as intermittent sensor error, sensor
compression, and user errors [13]. In addition to these, other fac-
tors associated with non-adherence to prescription PHDs include
knowledge/education, age, associated costs, psychosocial, usability,
and contextual factors [10, 15, 22, 32, 33, 36]. Nevertheless, the re-
sults of this paper highlight a critical dilemma. PHDs are developed
to enable ubiquitous monitoring of health status, however, if users
do not wear and use the devices consistently when not achieving
the target goals then the benefit is limited. Conversely, if users wear
and use the PHDs more often when they are achieving the target
goals then the recorded data may be slightly biased and not a true
reflection of the user’s BG status. This is particularly important
with regards to prescription PHDs, such as CGMs, given that doc-
tors and care-givers rely on this information to understand and
evaluate management and to guide treatment plans.
From our dataset-1, we found that majority of data gaps (≈ 80%)
occurred during the daytime between the hours of 6AM and 12AM
(i.e. midnight). Given that most users are likely to be awake and
able to make wearing choices during the daytime, this observation
is expected. However, we did not observe any significant differ-
ences between the average gap duration during the day versus at
night. We also observed more data gaps during the weekends (i.e.
Saturday and Sunday) compared to during the weekdays (i.e. Mon-
day - Friday). But there were no significant differences between the
average gap duration on weekdays vs. weekends.
To account for non-wearing behavior influenced by suboptimal
management, we recommend that particular attention should be
paid to the BG category users were in prior to the start of data gaps
(or missing data events). This knowledge can be implemented in
context-aware systems that include data-driven adherence analysis
in embedded algorithms. Currently, CGM manufacturers such as
Medtronic [23] and Dexcom [6] include "sensor wear (per week)"
and "sensor usage" in their reports for patients, caregivers, and
doctors. However, to the best of our knowledge, there is no analysis
on when CGM devices are taken off. Therefore, if there is a pattern
of users taking off their CGM device during periods of suboptimal
management, this insight will be missed. Such adherence analysis is
also applicable to other health domains inwhich PHDs are beneficial
[17], especially as it relates to chronic disease management. For
example, significant research has been committed toward wearable
PHDs for continuous monitoring of blood pressure, stress, mental
illness, and much more [2, 3, 5]. As wearable PHD become a reality
in other domains, adherence to these PHDs should be considered
with specific attention paid to management outcomes when data
gaps or missing data events occur. This analysis can inform targeted
interventions to improve adherence to PHDs and health outcomes.
Johnson et al. [17] present other application spaces in which PHDs
can serve dual-functions, namely for delivering medication and
monitoring adherence to medical devices.
7.1 Limitations
Despite the interesting results found in this study, there are limita-
tions that should be addressed in future work. First and foremost,
given that the dataset was contributed by active members of online
diabetes communities, these users are likely more invested in their
health and may have better outcomes than the population at large.
For example, Figure 4a shows the median wear time in both datasets
is greater than 22-hours/day. This is relatively uncommon for pre-
scription and non-prescription PHDs [15, 16, 24]. Additionally, the
subject-inclusion criteria for this research was > 65% wear-time for
the range of data contributed. Therefore, a more general dataset
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will likely showcase worse suboptimal management and lower ad-
herence to CGM or other PHDs. Nonetheless, as shown in Table
1, the datasets in this study included representative samples from
subjects with well-controlled and poorly-controlled diabetes based
on the ADA glycemic target criteria [1], therefore, we expect that
our results are reproducible.
Another limitation is the assumption that data gaps or missing
data are directly indicative of non-adherence to PHDs, specifically
CGMs in this case study. Majority of CGMs on the market today
use a disposable sensor that has a lifetime of about 3 - 14 days
depending on the device [36]. Therefore, some data gaps are ex-
pected for sensor replacement and device restart. Additionally, some
data gaps may be related to CGM battery replacement or recharge,
although these are less likely since the battery life of CGM transmit-
ters is about six months [42]. Future work will include follow-up
interviews with users to understand reasons for data gaps and non-
adherence to PHDs. This learning can further improve the design
of such devices.
8 CONCLUSION AND FUTUREWORK
To the best of our knowledge, the work presented in this paper is
one of the few studies that use quantitative, data-driven methods to
understand day-to-day factors that affect adherence to prescription
wearable medical devices. More specifically, our results suggest that
adherence to PHDs is influenced by performance toward the target
goal. With a focus on CGMs used in diabetes care, we found that ≈
33% of missing data occurred when users were not achieving their
goal of maintaining BG within the normal range. There was signifi-
cantly longer durations of missing data when users were farthest
away from the target goal (i.e. in extreme or more severe blood
glucose categories). Additionally, subjects with poorly-controlled
diabetes were observed to have significantly longer average data
gap durations than subjects with well-controlled diabetes. This
knowledge can inform the design of context-aware systems that
include data-driven adherence analysis in embedded algorithms
and provide interventions to improve outcomes.
As a starting point for future work, we recommend that PHD
adherence analysis should combine qualitative evaluations of non-
wearing behavior with data-driven analysis for a more compre-
hensive understanding of contributing factors. It is important to
note that there should be a distinction between non-prescription
PHDs and consumer wearable devices such as physical activity
trackers and prescription PHDs such as CGMs. Given that PHDs for
diabetes care are relatively advanced, this application space is ideal
for learning insights that can influence future development and use
of data from such devices. Future work following this study will
explore other contextual factors that influence missing data events
as well as good and/or suboptimal management in daily living. The
long-term goal is to develop data-driven decision-support tools to
improve health.
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